Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
*Close to a 100 patents pending
*Best in Class Performance
*Best In Class Value Price Per Dollar
*BIC Value Price Per Procedure
*Best in Class Mobility
*World Class Leadership
*World Class Partners...................
Wow the massive short 19,800 at 2.11
This is what JNJ is looking for NOT TITAN
Aug 20, 2018 · Ethicon Endosurgery of Johnson & Johnson, is recruiting for a Principal Preclinical Scientist ...See this and similar jobs on LinkedIn
6% Of Our Company
J.P. Morgan is worth around the amount of $2.534 trillion. It is the world's most valuable bank by market capitalization
Element 41 Please look into who is funding the IHU in Strasbourg France .... due some due diligence and you will find connections to Karl Storz, Medtronics, Verb and Johnson and Johnson....
Everyone finds the low hanging fruit no one digs for the gold
Re: diamond482
Post# 37473
If this got to $100 a share you would be looking at a 20 billion market cap. ISRG has a cap of 23b. I think it would take quite a long time to build that.
The hopeful outcome is clearly an acquisition by Verb or Medtronic. If Titan goes to market on its own, it will be a time consuming expensive process. They would have to higher a sales force and start the grind. The speculation of Verb does make a lot of sense, you have the JNJ field team in place, as well as the robotics arm of Google.
A Titan acquisition would put Verb in the market long before they could get there on there own. I do know that the ISRG team has Titan on their radar and clearly have some fear of the Titan Platform. I am not sure if ISRG would buy Titan or if they would even be allowed to buy Titan.
The best possible outcome from this is someone buying Titan, otherwise this is might take awhile.
Replies:
Well there sure as hell BETTER BE a
Honeycomb777 on 5/14/2016 6:45:57 PM
Report TOS
I hope we get to $12 by years end
LOAD THE F’N BOAT HUGE’AH
This is a ROCKETEER STRAIGHT TO THE MOON
Dr. Arnold P. Advincula, MD, FACS, FACOG (SAB) serves as Vice Chair of Women’s Health Gynecologic Surgery & Urogynecology. He was Clinical Professor of Obstetrics and Gynecology at CUMC. Dr. Advincula serves as Chief of Gynecology at the Sloane Hospital for Women at Columbia University Medical Center/New York Presbyterian Hospital. Dr. Advincula serves as Chief of the Division of Gynecologic Surgery at CUMC. He was Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He serves as a Member of Surgeon Advisory Board at Titan Medical Inc. Dr. Advincula serves as Member of Scientific Advisory Board at SurgiQuest, Inc. He is Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.
Forget pennies let’s shoot for the dolla dolla billz
RUNER RUNIN RANNING”A’bout”It
That is what me mudder in Ireland calls liquor - “stay away from those shorts”
That made me shite myself, Hoooooooooooooooold brave heart style.... long and strong, want to add but just so fed up, break even 14 hoping for massive partnership announcement any second now
They still left in 90 engineers in 11 different sites
3 Centers of Excellence
3 Plexus Sites ie Malaysia
That leaves 5 ?????
Question sites
What did you see that they took out?
Chairman of the board announced soon
A little birdie told me this is going to be bigger than big coin bigger than big coin I mean the biggest big coin
At Eurotech Ltd. our strategic mission is to identify and creatively solve the challenges facing today's businesses that utilize the internet for online video streaming, distribution, and networking. Eurotech Ltd. looks to seize new or existing, but previously unrecognized, web-ideas, and manage these in a manner that ensures their commercialization by bringing them to the forefront of their industries. We strive not to duplicate existing models, but go far beyond the expectations of the internet consumer, with mind-blowing technology and new dimensions of interactivity, never before experienced! We, like everyone else, recognize the current, aggressive climb of the social media explosion and are at the forefront of this rocketing trend.
God bless you Taco, you have talked me off the ledge of selling with your matter of fact conviction based on ur own due diligence.
The stock share price will not show a best in class robotic instrument that is poised to revolutionize the patient surgery arena
We are about to give Eagle Scouts in Robotic Surgery a lighter to start the campfire as opposed to the lint and steel they have had in years past
It is in the patents, and we have 220 million dollars invested along with the industry Giants recognizing the little engine that could
Let’s hope buyout is sooner than 18-24 months
Yup I have TITXD on TDAmeritrade at 6.65
Yup in my case Titan has to double and then some to break even
I talked to Sue Wilkins at Titan Front Desk. They do not have a phone number you can call in on, Titan will look into this in the future.
So just like BigT said, only way to watch or listen to it is to wait for Titan to post on website.
Let’s just say 100 bagger is not the destination 1000 + is the expectations
Since the initial U.S. FDA clearance in April 2014 for the da Vinci SP surgical system, Intuitive invested in important platform refinements. Intuitive plans to launch the da Vinci SP surgical system in the United States in a measured fashion, with customer shipments beginning in the third quarter of 2018.
Intuitive Surgical announced a new U.S. FDA clearance for the da Vinci SP surgical system for urologic surgical procedures that are appropriate for a single port approach.
The da Vinci SP system provides surgeons with robotic-assisted technology designed for deep and narrow access to tissue in the body. The ability to enter the body through a single, small incision helps surgeons perform more complex procedures. Intuitive anticipates pursuing further regulatory clearances for da Vinci SP, including transoral, transanal, and extraperitoneal applications, broadening the applicability of the SP platform over time.
“The da Vinci SP is the latest in our integrated product family that shows our commitment to improving minimally invasive surgery with technology that can positively impact patient outcomes,” said Gary Guthart, chief executive officer for Intuitive. “Our da Vinci SP compliments da Vinci X and Xi systems by enabling surgeons to access narrow workspaces while maintaining high quality vision, precision, and control that surgeons have come to trust from da Vinci systems.”
The da Vinci SP system includes three, multi-jointed, wristed instruments and the first da Vinci fully wristed 3D HD camera. The instruments and the camera all emerge through a single cannula and are properly triangulated around the target anatomy to avoid external instrument collisions that can occur in narrow surgical workspaces. The system enables flexible port placement and excellent internal and external range of motion (e.g., 360-degrees of anatomical access) through the single SP arm. Surgeons control the fully articulating instruments and the camera on the da Vinci SP system, which uses the same surgeon console as the da Vinci X and Xi systems."
That’s where your wrong taco, Patel, Mimic Software, Patents, Learning Centers, spell one hundred and fifty million reasons this is gonna be just another penny stock sticking it to the common joe investors, they snake oil us out of all our hard earn money’s and then we cry wolf...
LEZ GO TITXF/VERB/JNJ
A birdy told me that he has a feeling news is coming, and something donald trump HUGE-AH is coming
Something HUGE IS BREWING
GO TITAN GO TITXF
News ??? MJ ??? Crypto???
Cheers to Verb / Titan / JNJ Partnerships
Partnership with JNJ after we uplist, they pay the $50 Million to take us to
Promiseland
Verb/Titan Surgery 4.0
VERB/TITAN
Surgery 4.0 TITAN/VERB
Wow Auris & CMR ??? ROCKOMANIA
Your partnership predictions if correct would make this a CONGRATULATIONS LONGS Type of announcement
Worthy of a high five, slap on the ass, and a toast
ROCKO! TACO! Shhhhhh rocko taco rocko taco rocko taco
Boyz We are at the Right place at the right time, looking forward to the next few long and bumpy strong months ahead
Would a big partnership with a company like Medtronics raise pps??
Mazor Robotics & Medtronic Enter Next Phase of Strategic Partnership; Medtronic to Make a $40 million Third Tranche Investmen...
Source: Business Wire
Conference Call Today at 8:30 AM EDT (3:30PM IDT)
Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced that it has entered the next phase of its strategic partnership with Medtronic earlier than planned and their existing agreements have been amended accordingly. The agreements provide for the conversion of the commercial relationship between the parties, with Medtronic assuming exclusive worldwide distribution of the Mazor X system, and Medtronic making a $40 million third tranche investment in Mazor. These developments are a result of the early achievement of certain sales and marketing milestones by both companies, as well as higher than expected global market acceptance and demand for the Mazor X system. Medtronic and Mazor originally entered into a strategic agreement in May 2016.
Key Highlights Include:
Medtronic assumes exclusive global spine market commercial responsibility for the Mazor X Surgical Assurance Platform and its accessories.
The implementation of annual minimums for purchase of Mazor X systems by Medtronic with a cumulative potential of hundreds of Mazor X systems over a four and a half-year period.
Approximately 30 members of the current Mazor sales organization are expected to join Medtronic to assure continuation of the current momentum.
Co-development of future products for the spine market that combine Mazor Robotics’ core expertise in surgical planning and precision-guided surgical systems with Medtronic’s navigation capabilities and implant systems. The first results of this combined and synergistic effort are expected to be demonstrated this fall.
Mazor will continue to provide service to the global installed base of the Mazor X.
A shared economic incentive to continue developing products and services that maintain innovation leadership and utilization of Mazor Robotics clinical solutions.
Medtronic will invest $40 million in Mazor Robotics’ American Depository Shares (ADS) at a price of $38.46 per ADS, which represents the weighted average of the closing price of Mazor’s ADS on Nasdaq over the past 20 trading days. This third tranche of investment in Mazor by Medtronic will bring Medtronic’s total investment in Mazor to $72 million, representing approximately 11.9% of the outstanding shares post investment and 10.6% of the fully diluted shares outstanding post investment. Mazor will also issue to Medtronic warrants to purchase an additional 1.21 million Mazor ADSs at an exercise price of $44.23 per ADS. The exercise price represents a 15% premium over the per share price for the $40 million equity investment. Medtronic has the right to exercise the warrants immediately in whole or in part, for cash, and they expire after 18 months. Assuming the full exercise of the warrants, Medtronic’s investment in Mazor will reach $125 million and its ownership could increase to 4.2 million ADSs, or 14.2%, based on the current number of ADSs outstanding on a fully diluted basis. Closing of the $40 million equity investment is expected to take place on or around September 12, 2017.
“Medtronic is our valued strategic partner and together we have achieved the desired outcome for Phase I well ahead of our original plan,” commented Ori Hadomi, Chief Executive Officer. “I believe that the move to this next phase reinforces our significant leadership position in the growing market for surgical guidance systems for spine procedures. Our strategic partnership will allow hospitals in new markets around the world to have access to the Mazor X and gain the clinical benefits that this technology offers.
“The strategic partnership between Mazor and Medtronic has already resulted in 59 Mazor X system orders since the October 2016 launch and reflects an accelerated sales cycle due to customers’ eagerness to adopt our solutions for the spine market,” added Mr. Hadomi. “Now, as commercial responsibility for the Mazor X in the spine market shifts to Medtronic, the annual minimums for sale of Mazor X systems agreed to by the two companies are expected to drive substantial improvement in Mazor’s financial results during the next several years. Together we will be able to further advance our robust jointly-developed product pipeline for the spine market, to make a difference for patients while Mazor also pursues new opportunities to apply our innovative technologies to other medical needs.”
“Moving to the next phase of our strategic partnership demonstrates our shared passion for transforming how spine surgery is done,” said Doug King, senior vice president & president of the Medtronic Spine division, which is part of Medtronic's Restorative Therapies Group. “Mazor Robotics’ technology and Medtronic’s navigation capabilities and implant systems provide spine surgeons with complete procedural solutions that advance the standard of care and will help surgeons maximize predictability and efficiency.”
Mazor will continue to manufacture and recognize revenues for Mazor X system sales, disposable kits and service fees all of which will be sold at contractual pricing agreed with Medtronic. The contracted pricing is at a lower rate than Mazor realized through its direct sales channel. In addition, Mazor will be entitled to certain synergy fees associated with the use of Medtronic implants in Mazor Robotics' installed base. Moving from direct sales to a strategic distribution model is expected to immediately reduce Mazor’s annual operating expenses by approximately $13 million. Trailing 12-month operating expenses for Mazor totaled $52.7 million.
The proceeds from the investment will further strengthen Mazor’s balance sheet and provide the resources to continue to collaborate with Medtronic to develop innovative solutions for the spine market, as well as develop innovative solutions for other potential markets.
Mazor will continue to independently develop and market globally the Renaissance Surgical Guidance System, which was first launched in 2011. Efforts for Renaissance will be focused on certain market segments for which the Renaissance provides significant customer added value.
CONFERENCE CALL INFORMATION
The Company will host a conference call to discuss today’s announcement at 8:30 AM EDT (3:30 PM IDT). Investors within the United States interested in participating are invited to call 1-800-289-0498. Participants in Israel can use the toll-free dial-in number 1-80-925-8350. All other international participants can use the dial-in number 1-719-325-4818. For all callers, refer to Conference ID 1217133.
A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 1-866-375-1919 and reference the Replay Access Code: 1217133. All international callers can dial 1-719-457-0820, using the same Replay Access Code. To access the webcast, please visit www.mazorrobotics.com and select ‘Investor Relations.’
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance System enables surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit www.MazorRobotics.com.